Comparative genome-wide association studies of a depressive symptom phenotype in a repeated measures setting by race/ethnicity in the multi-ethnic study of atherosclerosis by Ware, Erin B et al.
RESEARCH ARTICLE Open Access
Comparative genome-wide association
studies of a depressive symptom phenotype
in a repeated measures setting by race/
ethnicity in the multi-ethnic study of
atherosclerosis
Erin B. Ware1,2*, Bhramar Mukherjee3, Yan V. Sun4, Ana V. Diez-Roux5, Sharon L.R. Kardia1 and Jennifer A. Smith1
Abstract
Background: Time-varying phenotypes have been studied less frequently in the context of genome-wide analyses
across ethnicities, particularly for mood disorders. This study uses genome-wide association studies of depressive
symptoms in a longitudinal framework and across multiple ethnicities to find common variants for depressive
symptoms. Ethnicity-specific GWAS for depressive symptoms were conducted using three approaches: a baseline
measure, longitudinal measures averaged over time, and a repeated measures analysis. We then used meta-analysis
to jointly analyze the results across ethnicities within the Multi-ethnic Study of Atherosclerosis (MESA, n = 6,335),
and then within ethnicity, across MESA and a sample from the Health and Retirement Study African- and European-
Americans (HRS, n = 10,163).
Methods: This study uses genome-wide association studies of depressive symptoms in a longitudinal framework
and across multiple ethnicities to find common variants for depressive symptoms. Ethnicity-specific GWAS for
depressive symptoms were conducted using three approaches: a baseline measure, longitudinal measures averaged
over time, and a repeated measures analysis. We then used meta-analysis to jointly analyze the results across
ethnicities within the Multi-ethnic Study of Atherosclerosis (MESA, n = 6,335), and then within ethnicity, across
MESA and a sample from the Health and Retirement Study African- and European-Americans (HRS, n = 10,163).
Results: Several novel variants were identified at the genome-wide suggestive level (5×10−8 < p-value ≤ 5×10−6) in
each ethnicity for each approach to analyzing depressive symptoms. The repeated measures analyses resulted in
typically smaller p-values and an increase in the number of single-nucleotide polymorphisms (SNP) reaching
genome-wide suggestive level.
Conclusions: For phenotypes that vary over time, the detection of genetic predictors may be enhanced by repeated
measures analyses.
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Psychogenetics
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Background
With advances in the ability of statistical software to
handle data with repeated measures, longitudinal data
analysis is becoming more feasible in genetic association
studies. While these analyses are more complicated and
computationally intensive than analyses using only base-
line measures, longitudinal data has been used to iden-
tify variants that influence complex traits above and
beyond that of cross-sectional measurements [1]. Be-
cause depressive symptoms may vary over time in rela-
tion to a variety of circumstantial factors, repeated
measures of depressive symptoms may provide a better
characterization of an individual’s phenotype than a sin-
gle measure, thus increasing power to detect genetic sus-
ceptibility loci.
There are a number of circumstances where longitu-
dinal data analysis may be more informative or powerful
than cross-sectional analyses based on single or time av-
eraged measures. If there is substantial variability over
time in the outcome or interaction of other covariates or
SNPs with time, a longitudinal analysis will clearly be
more informative [2]. For a given fixed number of obser-
vations, cross sectional analyses will be more powerful
than repeated measures in the presence of within-
subject correlations (e.g. cross sectional n = 500; re-
peated measures n = 250 with two measures), but longi-
tudinal analyses permits detection of factors associated
with within person changes over time, which often allows
stronger causal inferences [2]. A genetic association ana-
lysis with longitudinal data also follows these well-
established properties, except for the fact that the analysis
is repeated millions of times and tail behavior of the test
statistics along with robustness issues become more crit-
ical since much smaller significance thresholds are used
than traditional inference at a 5 % level of significance.
Depressive symptoms exist on a spectrum, varying in
both severity and duration, and are often measured in
population-based studies using the 20-item Center for
Epidemiological Studies Depression scale (CES-D). Given
the benefits of longitudinal analysis, the ability to detect
genetic predictors of depression may be enhanced by ana-
lyzing depressive symptoms both over time and quantita-
tively [3], rather than applying cutoffs or defining
disorders like Major Depressive Disorder (MDD) at the
extreme of the continuum for a single time point [4].
The Multi-Ethnic Study of Atherosclerosis (MESA)
European sub-sample was recently part of a discovery
sample for a cross-sectional genome-wide association
study (GWAS) of depressive symptoms conducted by
the Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) consortium [5]. This GWAS
focused on a single measure of depressive symptoms (as
assessed by CES-D) in individuals of European descent.
Though no loci reached genome-wide significance in the
discovery sample (composed of 34,549 individuals), one
of the seven most significant SNPs had a suggestive
association in the replication sample (rs161645, 5q21,
p = 9.19×10−3). This SNP reached genome-wide signifi-
cance (p = 4.78×10−8) in overall meta-analysis of the com-
bined discovery and replication samples (n = 51,258) [5].
Important limitations of this GWAS include the reliance
on a single measure of depressive symptoms and the focus
on a single race/ethnic group.
In the present study, we use longitudinal data on a
continuous measure of depressive symptoms collected
over a 9 year period from three exams in MESA to
conduct GWAS on depressive symptoms in four race/
ethnicities. We also contrast different approaches of
incorporating the repeated measures into the GWAS:
(1) analyzing a single time-point measure (baseline),
(2) averaging measures over time, and (3) conducting
a repeated measures outcome analyses. Finally, we
jointly analyze repeated measures GWAS results from
MESA and up to ten exams from the Health and Re-
tirement Study. The MESA study includes a total of
650, 507, and 5,178 participants with one, two, and three
measures, respectively, while the HRS sample consists of
34, 147, and 9,982 individuals with one, two, and three-
plus measures, respectively) in an overall meta-analysis for
European Americans and African Americans to increase
power. To our knowledge, there have been no GWAS of
repeated measures of depressive symptoms measured over
time in individuals of multiple race/ethnicities.
Results
Descriptive statistics
Descriptive statistics for MESA and HRS are presented
in Table 1. The MESA sample includes 6,335 individuals
(48 % male). Mean age at baseline is 62.2 years and ap-
proximately 40 %, 25 %, 12 %, and 23 % are of European
(EA), African (AA), Chinese (CA), and Hispanic (HA)
American self-reported ethnicity, respectively.
In MESA, the mean baseline depressive symptom score
ranged from 6.3 (standard deviation (SD): 6.6) in the CA
subsample to 9.9 (SD: 9.2) in the HA subsample out of a
possible score of 60. CES-D scores increased over time in
the EA (linear trend model for exam: βexam = 0.25, p <
0.0001), AA (βexam = 0.03, p = 0.67), and HA (βexam = 0.13,
p = 0.11) sub-groups, but this increase in trend was only
significant in EA. The CA sub-group showed a non-
significant decrease in depressive symptom score over
time (βexam = −0.04, p = 0.67). The intraclass correlation
(within-person correlation) across all exams for which an
individual had a valid CES-D score (up to three time-
points) ranged from 0.44 in AA to 0.60 in EA.
The HRS analysis sample contains 10,163 respondents
(41 % male), with 8,652 EA (85 %) and 1,511 AA (15 %).
Mean age at baseline was 58 years. The CES-D8
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depressive symptom score in HRS EA increased signifi-
cantly over study waves (βexam = 0.03, p < 0.0001) and de-
creased significantly in AA participants over time (βexam
= −0.01, p = 0.04). The intraclass correlation for the HRS
participants across exams was 0.48 for EA participants
and 0.51 for AA participants.
Ethnicity-specific association analysis in MESA
Table 2 shows the number of SNPs, minimum p-value of
the adjusted association between SNP dosage and outcome,
and the genomic-control inflation factor, lambda, for each
ethnicity in MESA and HRS. QQ plots are available in
Additional file 1. The inflation factor, the extent to which
the chi-square statistic is inflated due to confounding by
ethnicity [6], is very close to 1.0 for all analyses, indicating
adequate adjustment for population structure. One SNP
reached the genome-wide significant threshold in the HA
subset in the baseline CES-D approach in the intronic re-
gion of the MUC13 gene (rs1127233, 3q22.1, β = 0.2382, p-
value = 3.85×10−8; averaged β = 0.1598, p-value = 9.23×10−6;
Table 2 Minimum p-value from GWAS of baseline, averaged, and repeated measures of CES-D1 across ethnicities, MESA2 and HRS3
Baseline CES-D score Averaged CES-D score Repeated measures CES-D score
Study Ethnicity # of
SNPS
Min # of λ5 Min # of
unique
SNPs
λ Min # of
unique SNPs
λ
p-value unique SNPs4 p-value p-value
MESA
African American 2380122 2.05×10−7 7 1.01 6.64×10−7 9 1.00 1.63×10−7 11 1.01
European American 2166730 1.33×10−7 9 1.01 8.26×10−7 6 1.00 6.04×10−7 11 1.01
Chinese American 1801470 2.48×10−6 1 0.99 1.42×10−6 2 1.00 2.71×10−7 4 1.02
Hispanic American 2148331 3.85×10−8 10 1.00 1.61×10−6 4 1.00 9.25×10−7 11 1.01
HRS
African American 2446939 - - - - - - 2.07×10−6 - 1.01
European American 2177692 - - - - - - 6.54×10−7 - 1.04
1Center for Epidemiological Studies – Depression, 2Multi-Ethnic Study of Atherosclerosis, 3Health and Retirement Study, 4Number of unique (independent) SNPs,
linkage disequilibrium R2 < 0.80, INFO > 0.80, with ethnicity-specific minor allele frequency > 5 % and p-values < 1×10−5, 5genomic control lambda
Table 1 Descriptive statistics
MESA1 HRS2
n = 6,335 n = 10,163
European American African American Hispanic American Chinese American European American African American
n = 2,514 n = 1,603 n = 1,443 n = 775 n = 8,652 n = 1,511
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Depression score3
Baseline CES-D4 8 (7.8) 7.6 (7.6) 9.9 (9.2) 6.3 (6.6) 1.2 (1.8) 1.2 (1.8)
Averaged CES-D 8.7 (7.4) 7.8 (6.7) 10.2 (8.5) 6.2 (5.6) 1.2 (1.3) 1.9 (1.6)
Age 62.6 (10.2) 62.2 (10.1) 61.4 (10.3) 62.4 (10.4) 58.4 (8.8) 56.8 (8.2)
Sex (%) n % n % n % n % n % n %
Male 1207 48.0 744 46.4 711 49.3 385 49.7 3,556 41.1 639 42.3
Site (%)
Baltimore, MD 505 20.1 482 30.1 - - - - - - - -
Chicago, IL 526 20.9 258 16.1 - - 275 35.4 - - - -
Forsyth County, NC 548 21.8 425 26.5 3 0.2 - - - - - -
Los Angeles, CA 133 5.3 143 8.9 554 38.4 498 64.3 - - - -
New York, NY 209 8.3 295 18.4 431 29.9 2 0.3 - - - -
St. Paul, MN 593 23.6 - - 455 31.5 - - - - - -
Anti-depressant Use (%) 307 12.2 61 3.8 84 5.8 19 2.5 - - - -
Intraclass correlation
Repeated Measures CES-D 0.60 0.44 0.57 0.57 0.48 0.51
1Multi-Ethnic Study of Atherosclerosis, 2Health and Retirement Study, 3CES-D measured as 20-item sum in MESA and as 8-item sum in HRS, 4Center for
Epidemiologic Studies - Depression
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repeat measures β = 0.1753, p-value = 2.06×10−6). This gene
has previously been associated with cancer pathogenesis
(e.g. [7–16]) but has not been implicated in any psychiatric
disorders. This SNP was not associated with CES-D
in the other race/ethnicities nor did it show consistent dir-
ection across ethnicity in the baseline CES-D analyses
(AA: β = −0.0112, p-value = 0.7707; EA: β = −0.0228,
p-value = 0.4527; CA: β = 0.0562, p-value = 0.4351).
There were no other genome-wide significant SNPs
in any of the ethnicities for any of the baseline, aver-
age, and repeated-measures modeling approaches
though there were many suggestive p < 10−6 findings.
Comparison of results across approaches
To compare association results between the different
versions of the CES-D scores, we assessed scatter plots
for the p-values (p < 5×10−4) from each pair of SNPs for
the baseline CES-D score compared to the averaged
CES-D score phenotype (Additional file 2), the baseline
CES-D score compared to the repeated measures CES-D
score (Additional file 3), and the averaged CES-D score
against the repeated measures CES-D score (Additional
file 4) within each of the four ethnicities in MESA. For
all four ethnicities, the Spearman’s rank correlations be-
tween the baseline versus averaged CES-D phenotype
and between the baseline and repeated measures CES-D
phenotypes ranged between 0.46 and 0.57. The correla-
tions between p-values for the averaged versus repeated
measures CES-D phenotype ranged between 0.85 and
0.92 (Table 3). We observed an increase in the number
of unique (LD R2 < 0.8) genome-wide suggestive SNPs
from baseline to repeated measures for each ethnicity
(EA: eight to nine; AA: four to 11; CA: one to four; HA:
six to ten), with some (at least two SNPs appearing in
multiple approaches as genome-wide suggestive within
each ethnicity) consistency in the SNPs across approach
(Additional file 5).
Meta-analysis across ethnicities in MESA
The results from the three meta-analyses performed
within MESA across ethnicities for the baseline, aver-
aged, and repeated measures CES-D scores are pre-
sented in Table 4. In the table, we present every unique
(LD R2 < 80 %) SNP with p < 1×10−6. The meta-analysis
only included SNPs with ethnicity-specific minor allele
frequency (MAF) > 5 % calculated within ethnicity using
only MESA participants. These meta-analyses showed no
genome-wide significant results. Thirteen SNPs reached a
genome-wide suggestive threshold in these meta-
analyses. The smallest p-value was in the repeated
measures meta-analysis on chromosome 2, (rs41379347,
2q32.2, p-value = 1.81×10−7). This SNP was only present
(with MAF > 5 %) in the CA and HA subsamples. This
SNP is in the intronic region of the STAT1 gene, IFN-γ
transcription factor signal transducer and activator of
transcription 1, previously implicated as a tumor suppres-
sor [17, 18]. This SNP has not been previously associated
with depressive symptoms.
Joint-analysis across studies for EA and AA
Results from the joint-analyses (MESA +HRS) for EA
and AA, separately, are presented in Table 5. While no
SNP reached the genome-wide level, eight SNPs (EA
n = 3; AA n = 5) satisfied the suggestive threshold for sig-
nificance. In EA the smallest p-value (rs6842756, 4q35.1,
p-value = 6.54×10−7) was located within the ENPP6 gene,
which is expressed primarily in the kidney and brain and
has not been implicated in any disorders or diseases
[http://omim.org/]. In AA the smallest observed p-value
(rs2426733, 20q13.31, p-value = 2.07×10−6) was located
downstream of the RBM38 oncogene. RBM38 encodes an
RNA binding protein found to regulate MDM2 (12q14.3-
q15) gene expression through mRNA stability [19, 20],
but has not been identified in genetic studies of psychiatric
disorders [17] (http://omim.org/).
Meta-analysis across all ethnicities in MESA and HRS
For the meta-analysis across all ethnicities in both
HRS and MESA, we found no SNPs reaching
genome-wide significance, though we found seven
SNPs reaching genome-wide suggestive thresholds
(Table 5). The most strongly associated SNPs in the
meta-analysis, rs41379347 (p-value = 1.81×10−7) is lo-
cated on chromosome 2 (in the STAT1 gene). The
SNP rs41379347 was found previously in the MESA
Table 3 Spearman’s correlation coefficients and 95 % confidence intervals for paired p-values in Multi-Ethnic Study of
Atherosclerosis
Baseline vs averaged
CES-D score
Baseline vs repeated
measures CES-D score
Averaged vs repeated
measures CES-D score
r, (95 % Confidence interval) r, (95 % Confidence interval) r, (95 % Confidence interval)
MESA African American 0.53, (0.53, 0.53) 0.54, (0.54, 0.54) 0.88, (0.88, 0.88)
European American 0.54, (0.54, 0.54) 0.57, (0.57, 0.57) 0.92, (0.92, 0.92)
Chinese American 0.48, (0.48, 0.48) 0.46, (0.46, 0.47) 0.85, (0.85, 0.85)
Hispanic American 0.54, (0.54, 0.54) 0.56, (0.55, 0.56) 0.88, (0.88, 0.88)
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meta-analysis across ethnicity. This SNP was only
present (with MAF > 5 %) in the MESA CA and HA
samples, and thus, no new information was gained in
the joint analysis across MESA and HRS.
Consistency with previous GWAS on depressive symptom
scores
There has been one published GWAS conducted on de-
pressive symptom scores [5], for which MESA EA were
part of the discovery sample. This GWAS found one
genome-wide significant SNP in overall meta-analysis of
51,258 European-ancestry individuals (rs161645, 5q21,
p = 4.78×10−8). In our EA subsample, p-values for this
SNP in our baseline and repeated measures analysis
were 0.116 and 0.055, respectively, with consistent ef-
fect directions (+) as the Hek, et al. [5] finding.
Additionally, this SNP had a cross-ethnicity, within
MESA meta-analysis p-value of 0.067 in the baseline
analysis, 0.006 in the averaged CES-D analysis, and
0.008 in the repeated measures analysis. The overall
direction of effect was consistent with the published
GWAS for EA, AA, and HA, though the direction of
effect was opposite for CA. This SNP had p-values of
0.951 and 0.113 for the cross-study (i.e. combining
MESA and HRS) EA and AA analyses, respectively.
Discussion
This is the first set of GWASs to the authors’ know-
ledge, to investigate common genetic variants for de-
pressive symptoms in a longitudinal setting across four
different ethnicities. We performed GWASs within each
ethnicity for three different longitudinal approaches to a
depressive symptom phenotype (baseline, averaged, and
Table 4 Meta-analysis results1 across ethnicities in MESA2 (p-values < 1×10−5) for each depressive symptom score modeling
approach
Approach CHR SNP Location Coded allele Coded allele frequency Z-score P-value Direction3 Closest gene4 within ±50kB
Baseline
8 rs2440212 97270629 A 0.66 4.47 7.73×10−6 ++++ (GDF6)
9 rs13440434 131953827 A 0.87 −4.50 6.79×10−6 —— (GPR107)
10 rs7087469 54339854 A 0.13 4.76 1.93×10−6 ++?+ -
13 rs9560521 89457392 A 0.13 4.69 2.69×10−6 ++++ (LINC00559)
16 rs8046816 71863525 A 0.47 4.53 5.92×10−6 ++++ -
20 rs17215529 3923402 A 0.85 4.79 1.66×10−6 ++?+ RNF24
Averaged
1 rs3100865 2795967 T 0.49 4.44 9.02×10−6 ++++ -
2 rs41379347 191577187 T 0.89 −4.58 4.57×10−6 ??– STAT1
2 rs7602149 114357038 T 0.84 −4.57 4.78×10−6 –?- LOC728055
2 rs13001068 182706602 A 0.92 4.50 6.95×10−6 ? + ?+ (PDE1A)
7 rs697521 16730681 T 0.13 −4.74 2.12×10−6 –?- BZW2
8 rs7350109 60753909 A 0.81 −4.5 6.88×10−6 –?- -
11 rs1448128 121291660 C 0.24 −4.58 4.61×10−6 —— -
22 rs5760767 23696411 T 0.51 4.58 4.62×10−6 ++++ (TMEM211)
Repeated measures
1 rs11590206 145665933 A 0.16 −4.72 2.33×10−6 —— (GJA5)
2 rs41379347 191577187 T 0.89 −5.22 1.81×10−7 ??– STAT1
2 rs7602149 114357038 T 0.84 −4.62 3.83×10−6 –?- LOC728055
4 rs13139186 96637940 T 0.90 −4.48 7.44×10−6 —— UNC5C
4 rs233976 104823918 A 0.21 4.47 7.75×10−6 ?+++ TACR3
7 rs11771332 86539742 A 0.81 −4.48 7.45×10−6 ?-?- (KIAA1324L)
9 rs2211185 1332721 T 0.77 4.55 5.42×10−6 ++++ -
18 rs2728505 21474070 A 0.55 −4.47 7.84×10−6 —— -
22 rs5760767 23696411 T 0.51 4.54 5.68×10−6 ++++ (TMEM211)
1filtered at ethnicity-specific minor allele frequency 5 %, where the SNP was present in at least two ethnicities, linkage disequilibrium R2 < 80 %, and heterogeneity
p-value ≥ 0.1; 2Multi-Ethnic Study of Atherosclerosis; 3Order corresponding to direction positions: African, European, Chinese, Hispanic American; 4parentheses
indicate location outside of gene
Ware et al. BMC Genetics  (2015) 16:118 Page 5 of 11
repeated measures) and meta-analyzed them across eth-
nicity and across study. Though our joint meta-analysis
of all ethnicities in both studies comprises 16,498 indi-
viduals, and the power to detect genetic variants of de-
pression has been shown to increase when assessing
depression quantitatively — as opposed to using a di-
chotomous definition or cutoff point [21] — we did not
find any variants that reached genome-wide significant
levels in the European-, African-, Hispanic-, or Chinese-
American, race/ethnicity-specific GWAS, in meta-analyses
across ethnicity in MESA, or in joint analyses across study
for the European and African Americans with any evidence
of replication. However, we did find several novel variants
at a genome-wide suggestive level and we observed an in-
crease in the number of unique (LD R2 < 0.8) genome-wide
suggestive SNPs from baseline to repeated measures for
each ethnicity (Additional file 5). We have taken the single
SNP that has been credibly associated with depressive
symptoms from Hek et al., [5] and presented evidence that
a longitudinal framework may improve upon findings for
depressive symptoms.
Hek, et al. [5] identified a SNP (rs161645) associated
with a large sample of European-ancestry participants
measured at a single time point. It is important to note
Table 5 Meta-analysis results1 between MESA2 and HRS3 (p-values < 1×10−5) for repeated measures depressive symptom score GEE
analyses
Race CHR SNP Location Coded allele Coded allele frequency Z-score P-value Direction4,5 Closest gene6 within ±50kB
African American
1 rs10776776 114384683 T 0.55 4.73 2.30×10−6 ++ (SYT6)
1 rs1417303 235193008 T 0.59 −4.43 9.46×10−6 – LOC440737
2 rs4629180 101454802 A 0.83 −4.51 6.41×10−6 – (LOC731220)
2 rs6711630 126534599 T 0.93 4.58 4.70×10−6 ++
7 rs10249133 12514004 T 0.39 −4.47 7.67×10−6 – (LOC100133035)
8 rs17067630 3661853 A 0.85 4.70 2.57×10−6 ++ CSMD1
11 rs11036016 40661316 A 0.80 4.68 2.94×10−6 ++ LRRC4C
15 rs4551976 49264445 T 0.63 −4.45 8.48×10−6 – (CYP19A1)
16 rs365962 85267450 C 0.69 −4.53 5.83×10−6 – (LOC101928614)
20 rs2426733 55454729 A 0.40 −4.75 2.07×10−6 – (RBM38)
European American
1 rs12031875 71357685 A 0.82 4.81 1.54×10−6 ++ ZRANB2-AS2
4 rs6842756 185341452 A 0.92 4.98 6.54×10−7 ++ ENPP6
6 rs6941340 16145531 T 0.48 −4.47 7.95×10−6 –
9 rs11794102 111772109 A 0.91 4.54 5.70×10−6 ++ PALM2-AKAP2
13 rs6492314 110267411 C 0.28 −4.75 2.00×10−6 –
16 rs12921740 20219533 T 0.51 −4.55 5.44×10−6 – (GP2)
18 rs2612547 41290709 A 0.83 4.47 7.94×10−6 ++ SLC14A2
All samples
1 rs2300177 71270950 T 0.19 −4.56 5.09×10−6 ? − +−−? PTGER3
1 rs1539418 145676734 A 0.16 −4.53 5.87×10−6 ——??
1 rs7415169 168997688 A 0.85 4.70 2.58×10−6 ++++++
2 rs6711630 126534599 T 0.93 4.58 4.70×10−6 +????+
2 rs41379347 191577187 T 0.89 −5.22 1.81×10−7 ??–?? STAT1
4 rs6552764 185341497 A 0.86 4.64 3.41×10−6 − + ? − ++ ENPP6
8 rs12541177 124869454 T 0.31 −4.48 7.43×10−6 ———— FAM91A1
9 rs9408311 38704682 T 0.84 4.92 8.87×10−7 ++ − +++
15 rs16975781 94245464 T 0.90 4.62 3.83×10−6 +++++−
16 rs12921740 20219533 T 0.59 −4.70 2.61×10−6 -−− + −− (GP2)
1Filtered at ethnicity-specific minor allele frequency of 5 %, where the SNP was present in at least two ethnicities, linkage disequilibrium R2 < 80 %, and heterogeneity
p-value≥ 0.1; 2Multi-Ethnic Study of Atherosclerosis; 3Health and Retirement Study 4Order corresponding to direction positions: African, European, Chinese, Hispanic
American; 5For all samples analyses, order corresponding to direction position: MESA African American, MESA European American, MESA Chinese American, MESA
Hispanic American, HRS European American, HRS African American; 6parentheses indicate location outside of gene
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that European Americans from MESA were used in the
discovery sample for the previously published GWAS.
We found that in the EA subsample, repeated measures
better characterized depressive symptoms and the longi-
tudinal analysis resulted in a repeated measures p-value
for rs161645 (p = 0.055) less than half that of the base-
line measures model (p = 0.116). If we consider this SNP
a true signal (or proxy for a true signal), we indeed dem-
onstrate that the p-value has decreased from the base-
line to the repeated measures analysis.
A repeated measures analysis makes use of the full infor-
mation content in the outcome and exposure/covariates for
longitudinal data. For example, in an analysis with repeated
measures data, if there is drop-out in the study and we use
subject level averages, the homoscedasticity assumption of
linear models is violated as different averages will be based
on different number of observations and the ones with
more observation will have higher precision. Averaging the
exposure data may also lead to substantial loss in power. If
there is a time trend or interaction of covariates (or SNPs)
with time, a longitudinal model is expected to have larger
power than a cross-sectional or averaged model. Longitu-
dinal modeling is a better general framework as it allows in-
corporation of time-varying covariates (instead of averaging
them) and allows exploration of G × E interaction in
follow-up analysis with cumulative exposure trajectory. Al-
though we saw an increase in the number of unique
genome-wide suggestive SNPs for repeated measures com-
pared to baseline, we note that since most of the SNPs are
non-significant, this may be simply a comparison of false
positives. However, in view of the existing literature one
can argue that a longitudinal analysis is generally more effi-
cient than using a summary quantity in the presence of re-
peated measures data.
For repeated measures, there are multiple modeling
approaches. GEE produces unbiased and consistent esti-
mates of the fixed effect parameters, even under misspe-
cification of the correlation structure. Also, if the
correlation structure is correctly specified, there is gain
in terms of efficiency. GEE can be argued as a better
framework than a linear regression model in terms of its
robust estimates of the standard error and behavior of
QQ plots as it protects under model misspecification
[22]. That is why we chose the GEE framework for this
large-scale association analysis instead of an alternative
linear mixed model analysis.
Though GWAS have been used for over a decade, most
variants identified for diseases have had very modest effect
sizes, often explaining less than 1 % of the variance of
quantitative traits [23]. Because of the small effect sizes,
very large sample sizes are required to reach adequate
power to detect genetic effects and produce reliable infer-
ences [24]. Preliminary steps have been taken to increase
power in our study through the characterization of a
longitudinal phenotype. Most individual studies, including
this one, are underpowered to detect these variants and
often collaboration across many studies, involving meta-
analysis, are used to increase sample size, and thus power
[23, 25]. Though this framework is frequently used for
common traits with standard measures, it is exceedingly
difficult to find studies measuring depressive symptoms
using the CES-D in multiple ethnicities, across time.
The depressive symptom GWAS literature to date in-
cludes one GWAS, with only one genome-wide signifi-
cant result [5]. The literature for similar phenotypes,
such as Major Depressive Disorder (MDD), has nine
GWAS studies [26–34], a mega-analysis of the nine
GWAS that included almost 19,000 European unrelated
individuals [35], and a recent low-coverage, whole-
genome sequencing analysis in the Chinese ethnicity
[36]. Only two loci reached genome wide significance in
individual studies [28, 37], but these loci were not sig-
nificantly associated with MDD in the meta-analysis
[35]. The whole-genome sequencing analysis, using a
joint discovery-replication analysis and linear mixed
models including a genetic relatedness matrix as a ran-
dom effect, identified two loci on chromosome 10, one
near the SIRT1 gene (p = 2.53×10−10) and the other in an
intron of the LHPP gene (p = 6.45×10−12) [36]. Meta-
analyses of genetic predictors of MDD (up to early 2015)
are currently consistent with chance findings and hy-
pothesized candidate genes identified from physiological
pathways (such as TPH2, HTR2A, MAOA, COMT) have
rarely been identified/replicated as predictors of MDD in
GWAS [34, 38–40]. Accordingly, we did not find a sig-
nificant association with depressive symptoms for the
SNPs that reached genome-wide significance in MDD
GWAS nor those in hypothesized candidate genes. How-
ever, whole-genome sequencing and statistical modeling
alternatives to traditional linear regression provide a
promising avenue for discovering new genes that influ-
ence depressive illness, and follow-up of these new re-
gions will be imperative.
One potentially important reason that SNPs detected
through GWAS and biological candidate genes rarely repli-
cate is because despite the CES-D correlating strongly with
depression and having been used in hundreds of studies,
the CES-D is not a diagnostic tool. The CES-D only mea-
sures depressive symptoms over the past week. The MESA
study exams were spaced approximately 12 – 24 months
apart (the HRS surveys 24 months apart). It is possible that
failure to capture changes in depressive symptoms between
the assessments introduced measurement error in the
phenotype. Additionally, in the baseline and repeated mea-
sures analyses, though log-transformed to improve normal-
ity, the distribution of CES-D still deviated from the
normal distribution. This is a consistent limitation of CES-
D scores in the literature, and it should be noted that the p-
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values from our baseline and repeated measures models
may reflect the non-normal distribution of the phenotype.
We included only common variants (those with
ethnicity-specific MAF > 5 %) in our analysis. One rea-
son we may not have found any significant genetic vari-
ants of depressive symptoms is that we did not look at
rare variants or copy number variants. New methods for
analyzing rare variants or SNP sets, such as Sequence
Kernel Association Testing (SKAT), are being developed
and applied and may help to further elucidate genetic
predictors of depressive symptoms at a gene-level and
across ethnicities [41]. Additionally, it is possible that
multiple SNPs with small effects, working in concert,
could affect individual susceptibility to depression and
depressive symptoms [42]. Further, no interactions
(gene-gene or gene-environment) were evaluated in
these analyses, which may play an important role in re-
vealing the pathogenesis of depression and depressive
symptoms.
Conclusion
Since combining genetic information across ethnicities
can result in false-positive findings from population
stratification within genetically distinct populations, we
conducted GWASs separately by ethnicity adjusting for
ethnicity-specific principal components and filtered ini-
tial GWAS results by ethnicity-specific minor alleles to
remove low frequency variants for more robust findings.
The meta-analysis software accounts for both magnitude
and direction of effect when combining information
across studies (in this case different ethnicities) which is
especially appropriate when studies contain differences
in ethnicity, phenotype distribution, gender or con-
straints in sharing of individual level data [43].
Identifying genes that are associated with depression
has tremendous potential to transform our understand-
ing and treatment of depression. Utilizing longitudinal
measures in GWA studies for depressive symptoms al-
lows researchers to get a better picture of depression
over the life-course. Though this study did not find any
gene variants that reached genome-wide significance in
the repeated measures approach, it provides a first step
in examining depressive symptoms in different longitu-
dinal settings and also across multiple ethnicities.
Methods
Discovery sample
MESA is a longitudinal study supported by NHLBI with
the overall goal of identifying risk factors for subclinical
atherosclerosis [44]. The MESA cohort (N = 6,814) was
recruited in 2000–2002 from six Field Centers in Balti-
more, MD; Chicago, IL; Forsyth County, NC; Los
Angeles, CA; New York, NY; and St. Paul, MN. MESA
participants were 45–84 years of age and free of clinical
cardiovascular disease at baseline. Participants attended
a baseline examination and three additional follow-up
examinations approximately 18–24 months apart. At
each clinic visit, participants completed a series of
demographic, personal history, medical history, access to
care, behavioral, and psychosocial questionnaires in Eng-
lish, Spanish, or Chinese. Depressive symptoms were
assessed using the Center for Epidemiologic Studies De-
pression scale (CES-D) at exams 1, 3 and 4. The total
number of participants and the corresponding response
rates (of participants alive) were: exam 1 (n = 6,814),
exam 2 (n = 6,239, 92 %), exam 3 (n = 5,946, 89 %), exam
4 (n = 5,704, 87 %). After removing participants with
missing genetic data, depressive symptom score, or co-
variates used for analysis, the final sample size was 6,335
individuals (European (EA): 2,514; African (AA): 1,603;
Chinese (CA): 775; Hispanic (HA): 1,443). Data support-
ing the results of this article are available in the dbGaP
repository, phs000209.v12.p3, http://www.ncbi.nlm.nih.
gov/projects/gap/cgi-bin/study.cgi?study_id=phs000209.
v12.p3. Written informed consent was obtained from
participants after the procedure had been fully explained
and institutional review boards at each site approved study
protocol (University of Minnesota Human Subjects
Committee Institutional Review Board (IRB), Johns
Hopkins Office of Human Subjects Research IRB,
University of California Los Angeles Office for the
Protection of Research Subjects IRB, Northwestern
University Office for the Protection of Research Subjects
IRB, Wake Forest University Office of Research IRB,
Columbia University IRB).
Depressive symptom score
Depressive symptom score was assessed using the 20-
item CES-D Scale [45], which was for use in general
population surveys [45, 46]. The CES-D has an excellent
internal consistency (Cronbach’s alpha = 0.90) [45], and
assesses depressive symptoms at a specific period in time
(over the past week). The outcome measure for this ana-
lysis is a sum of the 20 items, ranging from 0 to 60. If
more than 5 items were missing, the CES-D score was
not calculated. If 1–5 items were missing, the scores
were summed for completed items, dividing the sum by
the number of questions answered and then multiplying
by 20. There were 5,178 (81.7 %) participants with three
measures of CES-D, 507 (8.0 %) with two measures, and
650 (10.3 %) with only baseline CES-D measures, for a
total of 17,198 observations. We corrected for anti-de-
pressant use through a similar algorithm to adjusting
blood pressure for persons taking anti-hypertensive medi-
cation [5]. Detailed methods are described in Additional
file 6. After adjustment for anti-depressant use, CES-D
scores were log-transformed to improve normality.
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Genotyping
Approximately one million SNPs were genotyped using
the Affymetrix Genome-Wide Human SNP Array 6.0. Im-
putation was performed using the IMPUTE 2.1.0 program
in conjunction with HapMap Phase I and II reference
panels (CEU + YRI + CHB + JPT, release 22 - NCBI Build
36 for AA, CA, and HA participants; CEU, release 24 -
NCBI Build 36 for EA). Imputation SNPs were filtered at
an INFO score of 0.80. We accounted for population sub-
structure by including the top four ethnicity-specific prin-
cipal components (estimated from genome-wide data) as
adjustment covariates in all analyses, as proposed previ-
ously by MESA investigators and elsewhere [47, 48].
Joint sample
The Health and Retirement Study (HRS) was used as a
joint sample to be combined with MESA GWAS results
in a meta-analysis [49]. These two studies have compar-
able participants, and similar measures of phenotype.
The HRS surveys a representative sample of more than
26,000 Americans over the age of 50 every two years
starting in 1992. HRS data includes information on de-
pressive symptoms measured with a short form of the
CES-D, the CES-D8. The CES-D8 includes a subset of
eight items from the full 20-item CES-D [45]. The de-
pression score for each participant was composed of the
total number of affirmative depression answers. The
HRS depression symptom score ranges from 0 to 8. Par-
ticipants missing two or more of the eight items were
excluded from the analyses. Written informed consent
was obtained and the IRB at the University of Michigan
approved study protocol before data collection.
Over 12,000 HRS participants were genotyped for
about 2.5 million SNPs using the Illumina Human
Omni-2.5 Quad beadchip. Genotypes were imputed for
EA and AA using MACH software (HapMap Phase II,
release #22, CEU panel for EA and CEU + YRI panel for
African Americans). Imputation SNPs were filtered at an
INFO score of 0.80. We accounted for population sub-
structure by including the top four ethnicity-specific
principal components (estimated from genome-wide
data) as adjustment covariates in all analyses. There were
10,163 HRS participants after removing those with miss-
ing outcome, covariate or genetic information. A total of
34 (0.3 %) had only one measure of CES-D8, 147 (1.4 %)
had two measures, and 9,982 (98.2 %) had three or more
CES-D8 measures, for a total of 72,273 observations.
Genome-wide association analysis
We contrasted GWAS results using different approaches
to incorporate the time-varying phenotypic data: using a
single (baseline) measure, taking the average across
exams, or conducting a repeated measures analysis that
accounts for correlation of responses within individuals.
Baseline and averaged GWA studies were analyzed
using a one-step linear regression approach, adjusting
for age, sex, site (in MESA) and the first four genome-
wide principal components, stratified by race in PLINK
v.1.07 [50, 51]. Each SNP was analyzed separately, using
SNP dosages, in an additive genetic model.
For the repeated measures, we used generalized estimat-
ing equations (GEE) to account for within-individual cor-
relations between repeated CES-D measures [52]. Within
the ‘geepack’ package in the R software, we used an ex-
changeable (compound symmetric) correlation structure
because empirical correlations for CES-D measures for
exam 1, 3, and 4 were similar and we saw no significant
trend in CES-D over time for any ethnicity except for the
EA sub-sample [53, 54].
Comparison of p-values across phenotype approach
To examine whether p-values from GWAS in MESA were
consistent in rank across the three analysis approaches
(baseline, averaged across exams, repeated measures), we
calculated Spearman’s correlations between the ranks of p-
values for SNP-phenotype associations within ethnic group.
Meta-analysis
To increase statistical power to detect SNP association,
we performed a fixed-effects meta-analysis combining
results across all four ethnicities within the MESA study
for each of the three phenotype definitions (baseline, av-
eraged, repeated measures), weighting by sample size. In
order to further investigate consistency of associations
across different studies we also conducted a meta-
analysis for EA and AA (separately) across the MESA
and HRS studies for the repeated measures phenotype.
We use only the AA and EA samples due to the availabil-
ity of a large enough sample size for these two ethnicities
in HRS. Finally, we performed a meta-analysis across all
ethnicities and all studies to further elucidate any genetic
variants across ethnicity. For the analysis that includes
both MESA and HRS, the repeated measures phenotype
was selected to allow for maximum power. All meta-
analyses were performed using METAL [43].
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genome-wide association studies for baseline CES-D score compared
to averaged CES-D score. CES-D: Center for Epidemiological Studies –
Depression, (a) African Americans, (b) European Americans, (c) Chinese
Americans, (d) Hispanic Americans. (EPS 1757 kb)
Additional file 3: Comparison of p-values (p-value < 5×10−4) for
genome-wide association studies for baseline CES-D score compared
to repeated measures CES-D score. CES-D: Center for Epidemiological
Studies – Depression, (a) African Americans, (b) European Americans,
(c) Chinese Americans, (d) Hispanic Americans. (EPS 1450 kb)
Additional file 4: Comparison of p-values (p-value < 5×10−4) for
genome-wide association studies for averaged CES-D score compared
to repeated measures CES-D score. CES-D: Center for Epidemiological
Studies – Depression, (a) African Americans, (b) European Americans,
(c) Chinese Americans, (d) Hispanic Americans. (EPS 1424 kb)
Additional file 5: Individual SNP information for unique SNPs
reaching genome-wide suggestive p-value threshold for MESA
ethnicity-specific GWAS analyses for each methodological approach
(MAF > 5 %, INFO > 0.8, LD R2 < 0.80). (PDF 110 kb)
Additional file 6: Methodological information on anti-depressant
adjustment. (PDF 269 kb)
Competing interests
Drs. Ware, Smith, Mukherjee, Sun, Diez-Roux, and Kardia declare no potential
conflicts of interest.
Authors’ contributions
EBW contributed to the design, data acquisition, analysis, interpretation of
the data, and writing and revising of the manuscript; JAS, BM, YVS, ADR, and
SLRK contributed to the design of the study, drafting of the manuscript,
critical evaluation of intellectual content, and data acquisition. All authors
have read and approved the final manuscript.
Authors’ information
Not applicable.
Acknowledgements
MESA and the MESA SHARe project are conducted and supported by the
National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA
investigators. Support for MESA is provided by contracts N01-HC-95159
through N01-HC-95169 and UL1-RR-024156. Funding for genotyping was
provided by NHLBI Contract N02-HL-6-4278 and N01-HC-65226. Support for
this study was also provided through R01-HL-101161.
HRS is supported by the National Institute on Aging (NIA U01AG009740). The
genotyping was funded separately by the National Institute on Aging (RC2
AG036495, RC4 AG039029). Genotyping was conducted by the NIH Center
for Inherited Disease Research (CIDR) at Johns Hopkins University.
Genotyping quality control and final preparation of the data were performed
by the Genetics Coordinating Center at the University of Washington.
Author details
1Department of Epidemiology, University of Michigan, Ann Arbor, MI, USA.
2Institute of Social Research, University of Michigan, 1415 Washington
Heights #4614, Ann Arbor, MI 48109, USA. 3Department of Biostatistics,
University of Michigan, Ann Arbor, MI, USA. 4Department of Epidemiology,
Emory University, Atlanta, GA, USA. 5Department of Epidemiology and
Biostatistics, Drexel University, Philadelphia, PA, USA.
Received: 4 December 2014 Accepted: 30 September 2015
References
1. Smith EN, Chen W, Kahonen M, Kettunen J, Lehtimaki T, Peltonen L, et al.
Longitudinal genome-wide association of cardiovascular disease risk factors
in the Bogalusa heart study. PLoS Genet. 2010;6(9):e1001094.
2. Diggle P, Heagery P, Kung-Yee L, Zeger S. Analysis of Longitudinal Data.
Oxford, United Kingdom: Oxford University Press; 2002.
3. Hettema JM, Neale MC, Myers JM, Prescott CA, Kendler KS. A population-
based twin study of the relationship between neuroticism and internalizing
disorders. Am J Psychiatry. 2006;163(5):857–64.
4. Kendler KS, Gardner Jr CO. Boundaries of major depression: an evaluation of
DSM-IV criteria. Am J Psychiatry. 1998;155(2):172–7.
5. Hek K, Demirkan A, Lahti J, Terracciano A, Teumer A, Cornelis MC, et al. A
Genome-Wide Association Study of Depressive Symptoms. Biol Psychiatry.
2013;73(7):667–78.
6. Devlin B, Roeder K. Genomic control for association studies. Biometrics.
1999;55(4):997–1004.
7. Chauhan SC, Ebeling MC, Maher DM, Koch MD, Watanabe A, Aburatani H,
et al. MUC13 mucin augments pancreatic tumorigenesis. Mol Cancer Ther.
2012;11(1):24–33.
8. Chauhan SC, Vannatta K, Ebeling MC, Vinayek N, Watanabe A, Pandey KK,
et al. Expression and functions of transmembrane mucin MUC13 in ovarian
cancer. Cancer Res. 2009;69(3):765–74.
9. Gupta BK, Maher DM, Ebeling MC, Sundram V, Koch MD, Lynch DW, et al.
Increased expression and aberrant localization of mucin 13 in metastatic
colon cancer. J Histochem Cytochem. 2012;60(11):822–31.
10. Maher DM, Gupta BK, Nagata S, Jaggi M, Chauhan SC. Mucin 13: structure,
function, and potential roles in cancer pathogenesis. Mol Cancer Res.
2011;9(5):531–7.
11. Moehle C, Ackermann N, Langmann T, Aslanidis C, Kel A, Kel-Margoulis O,
et al. Aberrant intestinal expression and allelic variants of mucin genes
associated with inflammatory bowel disease. J Mol Med. 2006;84(12):1055–66.
12. Samuels TL, Handler E, Syring ML, Pajewski NM, Blumin JH, Kerschner JE,
et al. Mucin gene expression in human laryngeal epithelia: effect of
laryngopharyngeal reflux. Ann Otol Rhinol Laryngol. 2008;117(9):688–95.
13. Shimamura T, Ito H, Shibahara J, Watanabe A, Hippo Y, Taniguchi H, et al.
Overexpression of MUC13 is associated with intestinal-type gastric cancer.
Cancer Sci. 2005;96(5):265–73.
14. Williams SJ, Wreschner DH, Tran M, Eyre HJ, Sutherland GR, McGuckin MA.
Muc13, a novel human cell surface mucin expressed by epithelial and
hemopoietic cells. J Biol Chem. 2001;276(21):18327–36.
15. Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, et al. The
secreted protein discovery initiative (SPDI), a large-scale effort to identify
novel human secreted and transmembrane proteins: a bioinformatics
assessment. Genome Res. 2003;13(10):2265–70.
16. Kimura K, Wakamatsu A, Suzuki Y, Ota T, Nishikawa T, Yamashita R, et al.
Diversification of transcriptional modulation: large-scale identification and
characterization of putative alternative promoters of human genes. Genome
Res. 2006;16(1):55–65.
17. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al.
dbSNP: the NCBI database of genetic variation. Nucleic Acids Res.
2001;29(1):308–11.
18. Hix LM, Karavitis J, Khan MW, Shi YH, Khazaie K, Zhang M. Tumor STAT1
transcription factor activity enhances breast tumor growth and immune
suppression mediated by myeloid-derived suppressor cells. J Biol Chem.
2013;288(17):11676–88.
19. Xu E, Zhang J, Chen X. MDM2 expression is repressed by the RNA-binding
protein RNPC1 via mRNA stability. Oncogene. 2013;32(17):2169–78.
20. Yan W, Zhang J, Zhang Y, Jung YS, Chen X. p73 expression is regulated by
RNPC1, a target of the p53 family, via mRNA stability. Mol Cell Biol.
2012;32(13):2336–48.
21. van der Sluis S, Posthuma D, Nivard MG, Verhage M, Dolan CV. Power
in GWAS: lifting the curse of the clinical cut-off. Mol Psychiatry.
2013;18(1):2–3.
22. Voorman A, Lumley T, McKnight B, Rice K. Behavior of QQ-plots and
genomic control in studies of gene-environment interaction. PLoS One.
2011;6(5):e19416.
23. de Bakker PI, Ferreira MA, Jia X, Neale BM, Raychaudhuri S, Voight BF.
Practical aspects of imputation-driven meta-analysis of genome-wide
association studies. Hum Mol Genet. 2008;17(R2):R122–128.
24. Roberts R, Wells GA, Stewart AF, Dandona S, Chen L. The genome-wide
association study–a new era for common polygenic disorders. J Cardiovasc
Transl Res. 2010;3(3):173–82.
25. McCarthy MI, Hirschhorn JN. Genome-wide association studies: past, present
and future. Hum Mol Genet. 2008;17(R2):R100–101.
26. Huang J, Perlis RH, Lee PH, Rush AJ, Fava M, Sachs GS, et al. Cross-disorder
genomewide analysis of schizophrenia, bipolar disorder, and depression.
Am J Psychiatry. 2010;167(10):1254–63.
Ware et al. BMC Genetics  (2015) 16:118 Page 10 of 11
27. Lewis CM, Ng MY, Butler AW, Cohen-Woods S, Uher R, Pirlo K, et al.
Genome-wide association study of major recurrent depression in the U.K.
population. Am J Psychiatry. 2010;167(8):949–57.
28. McMahon FJ, Akula N, Schulze TG, Muglia P, Tozzi F, Detera-Wadleigh SD,
et al. Meta-analysis of genome-wide association data identifies a risk locus
for major mood disorders on 3p21.1. Nat Genet. 2010;42(2):128–31.
29. Muglia P, Tozzi F, Galwey NW, Francks C, Upmanyu R, Kong XQ, et al.
Genome-wide association study of recurrent major depressive disorder in
two European case–control cohorts. Mol Psychiatry. 2010;15(6):589–601.
30. Rietschel M, Mattheisen M, Frank J, Treutlein J, Degenhardt F, Breuer R, et al.
Genome-wide association-, replication-, and neuroimaging study implicates
HOMER1 in the etiology of major depression. Biol Psychiatry.
2010;68(6):578–85.
31. Shi J, Potash JB, Knowles JA, Weissman MM, Coryell W, Scheftner WA, et al.
Genome-wide association study of recurrent early-onset major depressive
disorder. Mol Psychiatry. 2011;16(2):193–201.
32. Shyn SI, Shi J, Kraft JB, Potash JB, Knowles JA, Weissman MM, et al. Novel
loci for major depression identified by genome-wide association study of
Sequenced Treatment Alternatives to Relieve Depression and meta-analysis
of three studies. Mol Psychiatry. 2011;16(2):202–15.
33. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major
depression: Review and meta-analysis. Am J Psychiatr. 2000;157(10):1552–62.
34. Wray NR, Pergadia ML, Blackwood DH, Penninx BW, Gordon SD, Nyholt
DR, et al. Genome-wide association study of major depressive disorder:
new results, meta-analysis, and lessons learned. Mol Psychiatry.
2012;17(1):36–48.
35. Major Depressive Disorder Working Group of the Psychiatric GC. A mega-
analysis of genome-wide association studies for major depressive disorder.
Mol Psychiatry. 2013;18(4):497–511.
36. CONVERGE consortium. Sparse whole-genome sequencing identifies two
loci for major depressive disorder. Nature. 2015;523(7562):588–91.
37. Hek K, Mulder CL, Luijendijk HJ, van Duijn CM, Hofman A, Uitterlinden AG,
et al. The PCLO gene and depressive disorders: replication in a population-
based study. Hum Mol Genet. 2010;19(4):731–4.
38. Bosker FJ, Hartman CA, Nolte IM, Prins BP, Terpstra P, Posthuma D, et al.
Poor replication of candidate genes for major depressive disorder using
genome-wide association data. Mol Psychiatry. 2011;16(5):516–32.
39. Sullivan PF, de Geus EJ, Willemsen G, James MR, Smit JH, Zandbelt T, et al.
Genome-wide association for major depressive disorder: a possible role for
the presynaptic protein piccolo. Mol Psychiatry. 2009;14(4):359–75.
40. Wray NR, Pergadia ML, Blackwood DH, Penninx BW, Gordon SD, Nyholt DR,
et al. Genome-wide association study of major depressive disorder: new
results, meta-analysis, and lessons learned. Mol Psychiatry. 2012;17(1):36–48.
41. Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X. Rare-variant association testing
for sequencing data with the sequence kernel association test. Am J Hum
Genet. 2011;89(1):82–93.
42. Demirkan A, Penninx BW, Hek K, Wray NR, Amin N, Aulchenko YS, et al.
Genetic risk profiles for depression and anxiety in adult and elderly cohorts.
Mol Psychiatry. 2011;16(7):773–83.
43. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of
genomewide association scans. Bioinformatics. 2010;26(17):2190–1.
44. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, et al.
Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol.
2002;156(9):871–81.
45. Radloff L. The CES-D scale: A self-report depression scale for research in the
general population. Appl Psychol Meas. 1977;1:385–401.
46. Comstock GW, Helsing KJ. Symptoms of depression in two communities.
Psychol Med. 1976;6(4):551–63.
47. Setiawan VW, Doherty JA, Shu XO, Akbari MR, Chen C, De Vivo I, et al. Two
estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled
analysis in the Epidemiology of Endometrial Cancer Consortium. Cancer
Epidemiol Biomarkers Prev. 2009;18(1):242–7.
48. Sun YV, Peyser PA, Kardia SL. A common copy number variation on
chromosome 6 association with the gene expression level of endothelin 1
in transformed B lymphocytes from three racial groups. Circ Cardiovasc
Genet. 2009;2(5):483–8.
49. Juster FT, Suzman R. An Overview of the Health and Retirement Study.
J Hum Resour. 1995;30:[S7] of S7–S56.
50. Purcell S. PLINK 1.07. http://pngu.mgh.harvard.edu/purcell/plink/
51. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al.
PLINK: a tool set for whole-genome association and population-based
linkage analyses. Am J Hum Genet. 2007;81(3):559–75.
52. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous
outcomes. Biometrics. 1986;42(1):121–30.
53. R Core Team. R: A language and environment for statistical computing.
Vienna, Austria: R Foundation for Statistical Computing. 2014.http://www.R-
project.org/
54. Yan J, Hojsgaard S, Halekoh U. geepack: Generalized estimating equation
package, 2012. URL http://CRAN.R-project.org/package=geepack. R package
version 1.1-6.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ware et al. BMC Genetics  (2015) 16:118 Page 11 of 11
